Science 37 announced today that it has been recognized in the
Gartner Hype Cycle for Life Science Clinical Development, 2023. As
stated by Gartner, “This Hype Cycle explores innovative
technologies that are specifically relevant to life science
clinical development programs in the pharmaceutical, biotechnology,
diagnostics, medical device, research institutions, and contract
research sectors.”
"We are honored to be recognized in the Gartner Hype Cycle for
Digital Trials," said David Coman, Chief Executive Officer at
Science 37. "Innovation is core to our model, as we continue to
deliver faster, more inclusive, patient-friendly clinical
research."
According to the Gartner report, “Digital trials will transform
the trial process, leading to improved quality, reduced cost and
reduced trial cycle time. Initial gains include improvement in
patient experience, completion rate, medication adherence and trial
participation.” The report further states “We anticipate digital
trials to move faster, with greater ease in finding and attracting
subjects and optimizing existing data-cleaning processes. Digital
trials will put harder-to-measure disease conditions within reach
and make plain to researchers more subtle indicators of health with
digital wearables, dramatically impacting well-being.”
Science 37 is seeing the impact of decentralized clinical trials
across therapeutic areas, delivering faster enrollment, improved
retention rates, and a better participant experience, based on the
Company’s ability to find and enroll participants regardless of
location. From global pharmaceutical companies to emerging
biopharma companies, adoption is also accelerating, particularly in
light of the recent U.S. Food and Drug Administration’s (FDA’s)
draft guidance on Decentralized Clinical Trials which enables new
modalities for data collection.
Science 37's unique approach is a virtual site, or MetasiteTM,
which enables patients to participate in trials from the comfort of
their homes. With investigator oversight, the Metasite removes
boundaries and enhances the experience with flexible telemedicine
visits, remote data capture, and convenient scheduling times.
Powered by a proprietary platform enabling eConsent, ePRO,
telemedicine, scheduling, and wearable/device integration, the
Metasite drives unified study orchestration, greater compliance,
and high-quality data—reaching patients wherever they are.
Gartner, Hype Cycle for Life Science Clinical
Development, 2023, 21 July 2023. GARTNER and Hype Cycle
are registered trademarks of Gartner, Inc. and/or its affiliates in
the U.S. and internationally and is used herein with permission.
All rights reserved. Gartner does not endorse any vendor, product
or service depicted in its research publications, and does not
advise technology users to select only those vendors with the
highest ratings or other designation. Gartner research publications
consist of the opinions of Gartner’s research organization and
should not be construed as statements of fact. Gartner disclaims
all warranties, expressed or implied, with respect to this
research, including any warranties of merchantability or fitness
for a particular purpose.
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to accelerate clinical research by
enabling universal trial access for patients. Through our Metasite™
we reach an expanded population beyond the traditional site,
delivering on our goal of clinical research that works for
everyone—with greater patient diversity. Patients gain the
flexibility to participate from the comfort of their own homes, at
their local community provider, or at a traditional site when
needed. Our Metasite is powered by a proprietary technology
platform with in-house medical and operational experts that drive
uniform study orchestration, enabling greater compliance and
high-quality data. To learn more, visit www.science37.com, or email
science37@science37.com.
Cautionary Note Regarding Forward-Looking
Statements This press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37 and the markets in which it operates, and
Science 37’s anticipated growth and profitability. These
forward-looking statements generally are identified by the words
“believe,” “can,” “could”, “seek”, “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,”
“will be,” “will continue,” “will likely result” and similar
expressions. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to: (i)
the ability to maintain the listing of Science 37’s securities on
The Nasdaq Stock Market LLC, (ii) volatility in the price of
Science 37’s securities due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Science 37 operates, variations in performance across competitors,
changes in laws and regulations affecting Science 37’s business,
changes in its capital structure, and general economic and
financial market conditions, including fluctuations in currency
exchange rates, economic instability, and inflationary conditions
(iii) the ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional opportunities,
(iv) the risk that Science 37 may never achieve or sustain
profitability, (v) the risk that Science 37 will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all, (vi) failure to realize
anticipated cost savings, and (vii) risks related to general
economic and financial market conditions. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” section of Science 37’s Annual Report on Form
10-K for the fiscal year ended December 31, 2022 filed with the
U.S. Securities and Exchange Commission (the “SEC”) on March 6,
2023 and in the other documents filed by Science 37 from time to
time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Science 37
assumes no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as required by law. Science 37
does not give any assurance that Science 37 will achieve its
expectations.
MEDIA INQUIRIES:Grazia MohrenScience 37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Science 37 (NASDAQ:SNCE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024